Regeneron Pharmaceuticals Inc (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by equities research analysts at Canaccord Genuity in a report issued on Friday. They currently have a $375.00 price objective on the biopharmaceutical company’s stock. Canaccord Genuity’s price target suggests a potential downside of 1.84% from the stock’s current price.
Several other equities research analysts have also weighed in on REGN. Leerink Swann set a $448.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, February 11th. Evercore ISI set a $421.00 price target on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, January 8th. Robert W. Baird restated a “positive” rating and set a $379.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, December 12th. Vetr lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $401.26 price target on the stock. in a research report on Monday, December 12th. Finally, CIBC began coverage on Regeneron Pharmaceuticals in a research report on Friday. They set a “market perform” rating on the stock. Fourteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $434.97.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 382.02 on Friday. The company has a 50-day moving average price of $371.86 and a 200-day moving average price of $379.60. The stock has a market capitalization of $40.29 billion, a price-to-earnings ratio of 49.62 and a beta of 1.44. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $452.96.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.01. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The company had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.30 billion. During the same period in the previous year, the company posted $2.83 earnings per share. The firm’s revenue was up 11.7% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post $12.95 earnings per share for the current year.
Your IP Address:
In other news, major shareholder Sanofi acquired 87,298 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 11th. The stock was bought at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of REGN. Northwestern Mutual Wealth Management Co. boosted its stake in Regeneron Pharmaceuticals by 39.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,070 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 304 shares during the period. Macquarie Group Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 7.7% in the second quarter. Macquarie Group Ltd. now owns 35,214 shares of the biopharmaceutical company’s stock worth $12,298,000 after buying an additional 2,514 shares during the last quarter. Advisory Services Network LLC boosted its stake in shares of Regeneron Pharmaceuticals by 80.7% in the third quarter. Advisory Services Network LLC now owns 600 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 268 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 620 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 7 shares during the last quarter. Finally, Jacobs & Co. CA bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $345,000. Institutional investors own 68.83% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.